Advertisement
BDX vs RMD
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. ResMed Inc. (RMD) Stock Comparison
Key Takeaways
- BDX closed at $156.36 on July 24, 2026, with a year-to-date return of 3.87%, reflecting more modest performance compared to the broader market.
- RMD closed at $195.27 on the same date, delivering stronger year-to-date gains of 18.50% amid healthcare sector interest.
- Recent weeks saw multiple analyst downgrades for RMD, including lowered price targets, alongside its divestiture of the MatrixCare business to refocus on core operations.
- BDX is preparing to report fiscal third-quarter 2026 results, with analysts expecting an earnings decline of approximately 14.7%.
- Both stocks operate in the medical technology sector but differ in growth drivers, with BDX emphasizing diversified devices and RMD focused on respiratory care solutions.
- Market sentiment has shown relative stability for BDX versus increased scrutiny and volatility for RMD in recent market activity.
Introduction
Investors and traders often compare medical technology stocks to assess relative positioning within the healthcare sector. BDX and RMD represent established players with distinct business focuses, making their comparison relevant for those evaluating sector exposure, momentum, and risk profiles. This analysis examines observable performance metrics, recent developments, and market dynamics to provide a factual basis for understanding how these equities have behaved in the current environment.
BDX Overview and Recent Performance
Becton, Dickinson and Company develops and manufactures medical devices, instrument systems, and reagents used in healthcare settings worldwide. In recent market activity, BDX has traded in a range influenced by broader healthcare trends and company-specific operational updates. The stock closed at $156.36 on July 24, 2026, posting a 2.22% gain that day, though its year-to-date return stood at 3.87% and one-year return at 10.97%. Sentiment has been shaped by anticipation of upcoming fiscal third-quarter results and expectations of an earnings decline, alongside steady demand across its segments. The company maintains a diversified portfolio that supports relative resilience in fluctuating market conditions.
RMD Overview and Recent Performance
ResMed Inc. specializes in cloud-connected medical devices for sleep apnea, respiratory care, and other chronic conditions. RMD closed at $195.27 on July 24, 2026, up 1.76%, with stronger year-to-date performance of 18.50% and a one-year return of 27.90%. Recent market activity included a divestiture of its MatrixCare business in early July to sharpen focus on core sleep and respiratory offerings. Multiple analyst actions in mid-July, such as downgrades and reduced price targets from firms including RBC Capital and Jefferies, contributed to sentiment shifts. Earlier in the year, the company reported revenue growth that exceeded estimates in its first fiscal quarter.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of AI-powered trading bots from hundreds available across its platform. Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, yet only the highest-ranked and most suitable for prevailing market conditions appear in this curated section. Available bots exhibit varied trading styles, strategies, timeframes, performance metrics, and ticker sets, with some historical leaders showing returns up to +241% and win rates in the 70–80% range across sectors like semiconductors and small caps. These tools leverage adaptive models to respond to dynamic conditions. Review the Trending AI Robots page for additional details on current selections.
Head-to-Head Comparison
BDX and RMD both serve the medical technology space but differ in business models and exposures. BDX offers broad diversification across devices and diagnostics, supporting steadier cash flows, while RMD concentrates on respiratory solutions with higher growth potential tied to chronic disease management. Recent momentum favors RMD on a year-to-date basis, though BDX has shown less volatility in response to sector news. Risk factors include regulatory pressures and reimbursement changes for both, with RMD additionally navigating post-divestiture adjustments. Market sentiment reflects analyst caution toward RMD versus more neutral positioning for BDX ahead of earnings.
Tickeron AI Verdict
Based on observable factors such as trend consistency and relative stability in recent market activity, Tickeron’s AI would likely assign a modest probabilistic edge to BDX at present. Its diversified operations and lower recent volatility may align better with models emphasizing resilience amid mixed analyst signals affecting RMD. This assessment draws from performance differentials and positioning rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Hold and RMD is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 2 FA rating(s) are green whileRMD’s FA Score has 1 green FA rating(s).
- BDX’s FA Score: 2 green, 3 red.
- RMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 6 TA indicator(s) are bullish while RMD’s TA Score has 6 bullish TA indicator(s).
- BDX’s TA Score: 6 bullish, 4 bearish.
- RMD’s TA Score: 6 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +5.92% price change this week, while RMD (@Pharmaceuticals: Other) price change was +8.05% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
Reported Earning Dates
BDX is expected to report earnings on Aug 06, 2026.
RMD is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BDX | RMD | BDX / RMD | |
| Capitalization | 45.6B | 30.6B | 149% |
| EBITDA | 4.97B | 2.18B | 228% |
| Gain YTD | 9.983 | -11.945 | -84% |
| P/E Ratio | 28.90 | 20.35 | 142% |
| Revenue | 22.2B | 5.54B | 401% |
| Total Cash | N/A | 1.66B | - |
| Total Debt | 17.3B | 843M | 2,052% |
BDX | RMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 38 | |
PRICE GROWTH RATING 1..100 | 26 | 58 | |
P/E GROWTH RATING 1..100 | 69 | 84 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (8) in the Medical Specialties industry is in the same range as RMD (14). This means that BDX’s stock grew similarly to RMD’s over the last 12 months.
BDX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RMD (100). This means that BDX’s stock grew similarly to RMD’s over the last 12 months.
RMD's SMR Rating (38) in the Medical Specialties industry is somewhat better than the same rating for BDX (87). This means that RMD’s stock grew somewhat faster than BDX’s over the last 12 months.
BDX's Price Growth Rating (26) in the Medical Specialties industry is in the same range as RMD (58). This means that BDX’s stock grew similarly to RMD’s over the last 12 months.
BDX's P/E Growth Rating (69) in the Medical Specialties industry is in the same range as RMD (84). This means that BDX’s stock grew similarly to RMD’s over the last 12 months.
| BDX | RMD | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 82% | 4 days ago 71% |
| Stochastic ODDS (%) | 4 days ago 57% | 4 days ago 66% |
| Momentum ODDS (%) | 4 days ago 51% | 4 days ago 63% |
| MACD ODDS (%) | 4 days ago 56% | 4 days ago 44% |
| TrendWeek ODDS (%) | 4 days ago 47% | 4 days ago 58% |
| TrendMonth ODDS (%) | 4 days ago 49% | 4 days ago 57% |
| Advances ODDS (%) | 6 days ago 44% | 6 days ago 57% |
| Declines ODDS (%) | 12 days ago 43% | 12 days ago 60% |
| BollingerBands ODDS (%) | 4 days ago 55% | 4 days ago 73% |
| Aroon ODDS (%) | 4 days ago 50% | 4 days ago 57% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +0.10% | ||
| COO - BDX | 54% Loosely correlated | -0.45% | ||
| TMO - BDX | 50% Loosely correlated | -0.43% | ||
| BAX - BDX | 49% Loosely correlated | -2.21% | ||
| CNMD - BDX | 48% Loosely correlated | -1.45% | ||
| SOLV - BDX | 47% Loosely correlated | -1.59% | ||
More | ||||
RMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with COO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | +1.16% | ||
| COO - RMD | 50% Loosely correlated | -0.45% | ||
| SOLV - RMD | 48% Loosely correlated | -1.59% | ||
| BAX - RMD | 46% Loosely correlated | -2.21% | ||
| BDX - RMD | 45% Loosely correlated | +0.10% | ||
| ISRG - RMD | 43% Loosely correlated | +0.10% | ||
More | ||||